SAN DIEGO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Leerink Partners 7th Annual Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Thursday, February 15, 2018 at 11:30 a.m. EST (8:30 a.m. PST). The conference will be held from February 14-15 in New York.
A live audio webcast of the presentation will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The company’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
Pete De Spain
Vice President, Investor Relations &
Kura Oncology, Inc.
Robert H. Uhl
Westwicke Partners, LLC